Abeona Therapeutics ABEO

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    -$0.14 (-2.64%)Past DayToday's Volume:
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Business overview of Abeona Therapeutics (ABEO)
    Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel AIM.

    Key Insights

    Critical company metrics and information

    • Latest Closing Price

      $5.16

    • Market Cap

      $224.31 Million

    • Price-Earnings Ratio

      -8.19

    • Total Outstanding Shares

      43.47 Million Shares

    • Total Employees

      84

    • Dividend

      No dividend

    • IPO Date

      September 19, 1980

    • SIC Description

      Pharmaceutical Preparations

    • Primary Exchange

      NASDAQ

    • Type

      Common Stock

    • Headquarters

      6555 carnegie ave, 4th floor, Cleveland, OH, 44103

    • Homepage

      https://www.abeonatherapeutics.com

    Historical Stock Splits

    If you bought 25 shares of ABEO before July 5, 2022, you'd have 1 share today.
    Execution DateSplit Amount
    July 5, 20221-for-25 (Reverse Split)

    Cash Flow Statement

    July 1, 2024 to September 30, 2024
    MetricValue
    Net Cash Flow From Operating Activities$-12.23 Million
    Net Cash Flow, Continuing$-18.70 Million
    Net Cash Flow From Financing Activities, Continuing$-299,000
    Net Cash Flow$-18.70 Million
    Net Cash Flow From Financing Activities$-299,000
    Net Cash Flow From Operating Activities, Continuing$-12.23 Million

    Income Statement

    July 1, 2024 to September 30, 2024
    MetricValue
    Nonoperating Income/Loss$145,000
    Depreciation and Amortization$500,000
    Net Income/Loss Available To Common Stockholders, Basic$-30.27 Million
    Income/Loss From Continuing Operations Before Tax$-30.27 Million
    Net Income/Loss Attributable To Parent$-30.27 Million
    Operating Expenses$15.35 Million

    Comprehensive Income

    July 1, 2024 to September 30, 2024
    MetricValue
    Other Comprehensive Income/Loss$50,000
    Comprehensive Income/Loss$-30.22 Million
    Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
    Comprehensive Income/Loss Attributable To Parent$-30.22 Million

    Balance Sheet

    July 1, 2024 to September 30, 2024
    MetricValue
    Other Non-current Assets$3.88 Million
    Current Assets$112.66 Million
    Other Current Assets$2.66 Million
    Noncurrent Liabilities$56.40 Million
    Noncurrent Assets$7.93 Million
    Accounts Payable$2.79 Million

    Historical Dividends

    Announcement DatePayment DateRecord DateAmountFrequency
    No historical dividends

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about ABEO from trusted financial sources
      Boost your savings and earn 4.15% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
      All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

      â“’ 2025 Financhle. All Rights Reserved.